Novel αO-conotoxin GeXIVA[1,2] Nonaddictive Analgesic with Pharmacokinetic Modelling-Based Mechanistic Assessment

αO-conotoxin GeXIVA[1,2] was isolated in our laboratory from Conus generalis, a snail native to the South China Sea, and is a novel, nonaddictive, intramuscularly administered analgesic targeting the α9α10 nicotinic acetylcholine receptor (nAChR) with an IC50 of 4.61 nM. However, its pharmacokinetics and related mechanisms underlying the analgesic effect remain unknown. Herein, pharmacokinetics and multiscale pharmacokinetic modelling in animals were subjected systematically to mechanistic assessment for αO-conotoxin GeXIVA[1,2]. The intramuscular bioavailability in rats and dogs was 11.47% and 13.37%, respectively. The plasma exposure of GeXIVA[1,2] increased proportionally with the experimental dose. The plasma protein binding of GeXIVA[1,2] differed between the tested animal species. The one-compartment model with the first-order absorption population pharmacokinetics model predicted doses for humans with bodyweight as the covariant. The pharmacokinetics-pharmacodynamics relationships were characterized using an inhibitory loss indirect response model with an effect compartment. Model simulations have provided potential mechanistic insights into the analgesic effects of GeXIVA[1,2] by inhibiting certain endogenous substances, which may be a key biomarker. This report is the first concerning the pharmacokinetics of GeXIVA[1,2] and its potential analgesic mechanisms based on a top-down modelling approach.

[1]  Hui Zhang,et al.  Lyophilization Serves as an Effective Strategy for Drug Development of the α9α10 Nicotinic Acetylcholine Receptor Antagonist α-Conotoxin GeXIVA[1,2] , 2021, Marine drugs.

[2]  A. Sakamoto,et al.  Endothelin receptor type A is involved in the development of oxaliplatin-induced mechanical allodynia and cold allodynia acting through spinal and peripheral mechanisms in rats , 2021, Molecular pain.

[3]  Yan-yan Chu,et al.  Medicinal chemistry, pharmacology, and therapeutic potential of α-conotoxins antagonizing the α9α10 nicotinic acetylcholine receptor. , 2020, Pharmacology & therapeutics.

[4]  Ulrich Dirnagl,et al.  The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research* , 2020, BMC Veterinary Research.

[5]  Esther J Pearl,et al.  The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research , 2020, PLoS biology.

[6]  Yong-Qing Wang,et al.  The Impact of Plasma Protein Binding Characteristics and Unbound Concentration of Voriconazole on Its Adverse Drug Reactions , 2020, Frontiers in Pharmacology.

[7]  Dongting Zhangsun,et al.  Preclinical research of analgesic αO-conotoxin GeXIVA without addiction side effect. , 2020, Toxicon.

[8]  Xiaopeng Zhu,et al.  Effects of Cyclization on Activity and Stability of α-Conotoxin TxIB , 2020, Marine drugs.

[9]  Taolue Wu,et al.  Intra-articular delivery of celastrol by hollow mesoporous silica nanoparticles for pH-sensitive anti-inflammatory therapy against knee osteoarthritis , 2020, Journal of Nanobiotechnology.

[10]  D. Craik,et al.  Structure and Activity Studies of Disulfide-Deficient Analogues of αO-Conotoxin GeXIVA. , 2020, Journal of medicinal chemistry.

[11]  D. Craik,et al.  Conotoxins: Chemistry and Biology. , 2019, Chemical reviews.

[12]  Dongting Zhangsun,et al.  DSPE-PEG Modification of α-Conotoxin TxID , 2019, Marine drugs.

[13]  R. Su,et al.  The α9α10 Nicotinic Acetylcholine Receptor Antagonist αO-Conotoxin GeXIVA[1,2] Alleviates and Reverses Chemotherapy-Induced Neuropathic Pain , 2019, Marine drugs.

[14]  J. Lötsch,et al.  Potential biomarkers for persistent and neuropathic pain therapy. , 2019, Pharmacology & therapeutics.

[15]  Dongting Zhangsun,et al.  Discovery Methodology of Novel Conotoxins from Conus Species , 2018, Marine drugs.

[16]  S. Jacob,et al.  Dose translation between laboratory animals and human in preclinical and clinical phases of drug development , 2018, Drug development research.

[17]  D. Servent,et al.  α9‐containing nicotinic acetylcholine receptors and the modulation of pain , 2018, British journal of pharmacology.

[18]  Dongting Zhangsun,et al.  Effects of serum, enzyme, thiol, and forced degradation on the stabilities of αO‐Conotoxin GeXIVA[1,2] and GeXIVA [1,4] , 2018, Chemical biology & drug design.

[19]  Irina Vetter,et al.  Methods Used to Evaluate Pain Behaviors in Rodents , 2017, Front. Mol. Neurosci..

[20]  E. Glowatzki,et al.  RgIA4 Potently Blocks Mouse α9α10 nAChRs and Provides Long Lasting Protection against Oxaliplatin-Induced Cold Allodynia , 2017, Front. Cell. Neurosci..

[21]  Michael J. O'Donovan,et al.  Identification of a novel spinal nociceptive-motor gate control for Aδ pain stimuli in rats , 2017, eLife.

[22]  D. Craik,et al.  αO-Conotoxin GeXIVA disulfide bond isomers exhibit differential sensitivity for various nicotinic acetylcholine receptors but retain potency and selectivity for the human α9α10 subtype , 2017, Neuropharmacology.

[23]  M. Saulino,et al.  The Polyanalgesic Consensus Conference (PACC): Recommendations on Intrathecal Drug Infusion Systems Best Practices and Guidelines , 2017, Neuromodulation : journal of the International Neuromodulation Society.

[24]  R. Freeman,et al.  Neuropathic pain , 1999, The Lancet.

[25]  R. Baron,et al.  Neuropathic Pain , 2016, Seminars in Neurology.

[26]  C. Ghelardini,et al.  The α9α10 nicotinic receptor antagonist α-conotoxin RgIA prevents neuropathic pain induced by oxaliplatin treatment , 2016, Experimental Neurology.

[27]  Dongting Zhangsun,et al.  Anti-hypersensitive effect of intramuscular administration of αO-conotoxin GeXIVA[1,2] and GeXIVA[1,4] in rats of neuropathic pain , 2016, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[28]  D. Craik,et al.  Cloning, synthesis, and characterization of αO-conotoxin GeXIVA, a potent α9α10 nicotinic acetylcholine receptor antagonist , 2015, Proceedings of the National Academy of Sciences.

[29]  R. Baron,et al.  Neuropathic pain: principles of diagnosis and treatment. , 2015, Mayo Clinic proceedings.

[30]  A. Dahan,et al.  Translational PK–PD modeling in pain , 2012, Journal of Pharmacokinetics and Pharmacodynamics.

[31]  W. Lu,et al.  Application of model-based methods to characterize exenatide-loaded double-walled microspheres: in vivo release, pharmacokinetic/pharmacodynamic model, and in vitro and in vivo correlation. , 2012, Journal of pharmaceutical sciences.

[32]  B. Meibohm,et al.  Pharmacokinetics and Pharmacodynamics of Therapeutic Peptides and Proteins , 2012 .

[33]  Alec B. O’Connor Neuropathic Pain , 2012, PharmacoEconomics.

[34]  D. Betancur-Ancona,et al.  Bioavailability of Bioactive Peptides , 2011 .

[35]  N. Absalom,et al.  Alpha9 nicotinic acetylcholine receptors and the treatment of pain. , 2009, Biochemical pharmacology.

[36]  J. P. Perez Ruixo,et al.  Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[37]  Varun Garg,et al.  Comparison of four basic models of indirect pharmacodynamic responses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.

[38]  W. Jusko,et al.  Pharmacokinetic–Pharmacodynamic Modeling of Tolmetin Antinociceptive Effect in the Rat Using an Indirect Response Model: A Population Approach , 1998, Journal of Pharmacokinetics and Biopharmaceutics.

[39]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[40]  B. J. Winterson,et al.  Paw withdrawal thresholds and persistent hindlimb flexion in experimental mononeuropathies. , 2003, The journal of pain : official journal of the American Pain Society.

[41]  J. Riviere,et al.  Mixed-effects modeling of the interspecies pharmacokinetic scaling of oxytetracycline. , 2002, Journal of pharmaceutical sciences.

[42]  Editorial: Bioavailability after intramuscular injection. , 1975, The Lancet.